Efforts to control the errant products of a targeted in vivo generator

Jaspreet Singh Jaggi, Barry J. Kappel, Michael R. McDevitt, George Sgouros, Carlos D. Flombaum, Catalina Cabassa, David A. Scheinberg

Research output: Contribution to journalArticle

Abstract

Alpha-particle immunotherapy by targeted α-emitters or α-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 ( 225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radio-nuclides. The daughters, especially bismuth-213 ( 213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195- 225 Ac generator. 223Ac, francium-221 ( 221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P <0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P <0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P <0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P <0.0001). Competitive antagonism by bismuth sub-nitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P <0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.

Original languageEnglish (US)
Pages (from-to)4888-4895
Number of pages8
JournalCancer Research
Volume65
Issue number11
DOIs
StatePublished - Jun 1 2005

Fingerprint

Unithiol
Kidney
Chlorothiazide
Furosemide
Succimer
Metals
Tumor Burden
Francium
Actinium
Alpha Particles
Therapeutics
Bismuth
Diuresis
Radio
Isotopes
Immunotherapy
Haplorhini
Pharmacokinetics
Injections
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jaggi, J. S., Kappel, B. J., McDevitt, M. R., Sgouros, G., Flombaum, C. D., Cabassa, C., & Scheinberg, D. A. (2005). Efforts to control the errant products of a targeted in vivo generator. Cancer Research, 65(11), 4888-4895. https://doi.org/10.1158/0008-5472.CAN-04-3096

Efforts to control the errant products of a targeted in vivo generator. / Jaggi, Jaspreet Singh; Kappel, Barry J.; McDevitt, Michael R.; Sgouros, George; Flombaum, Carlos D.; Cabassa, Catalina; Scheinberg, David A.

In: Cancer Research, Vol. 65, No. 11, 01.06.2005, p. 4888-4895.

Research output: Contribution to journalArticle

Jaggi, JS, Kappel, BJ, McDevitt, MR, Sgouros, G, Flombaum, CD, Cabassa, C & Scheinberg, DA 2005, 'Efforts to control the errant products of a targeted in vivo generator', Cancer Research, vol. 65, no. 11, pp. 4888-4895. https://doi.org/10.1158/0008-5472.CAN-04-3096
Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C et al. Efforts to control the errant products of a targeted in vivo generator. Cancer Research. 2005 Jun 1;65(11):4888-4895. https://doi.org/10.1158/0008-5472.CAN-04-3096
Jaggi, Jaspreet Singh ; Kappel, Barry J. ; McDevitt, Michael R. ; Sgouros, George ; Flombaum, Carlos D. ; Cabassa, Catalina ; Scheinberg, David A. / Efforts to control the errant products of a targeted in vivo generator. In: Cancer Research. 2005 ; Vol. 65, No. 11. pp. 4888-4895.
@article{a46d8bb1aaed4f0aa1dcaf0277d931e2,
title = "Efforts to control the errant products of a targeted in vivo generator",
abstract = "Alpha-particle immunotherapy by targeted α-emitters or α-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 ( 225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radio-nuclides. The daughters, especially bismuth-213 ( 213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195- 225 Ac generator. 223Ac, francium-221 ( 221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P <0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P <0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P <0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P <0.0001). Competitive antagonism by bismuth sub-nitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P <0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.",
author = "Jaggi, {Jaspreet Singh} and Kappel, {Barry J.} and McDevitt, {Michael R.} and George Sgouros and Flombaum, {Carlos D.} and Catalina Cabassa and Scheinberg, {David A.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-04-3096",
language = "English (US)",
volume = "65",
pages = "4888--4895",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Efforts to control the errant products of a targeted in vivo generator

AU - Jaggi, Jaspreet Singh

AU - Kappel, Barry J.

AU - McDevitt, Michael R.

AU - Sgouros, George

AU - Flombaum, Carlos D.

AU - Cabassa, Catalina

AU - Scheinberg, David A.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Alpha-particle immunotherapy by targeted α-emitters or α-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 ( 225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radio-nuclides. The daughters, especially bismuth-213 ( 213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195- 225 Ac generator. 223Ac, francium-221 ( 221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P <0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P <0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P <0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P <0.0001). Competitive antagonism by bismuth sub-nitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P <0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.

AB - Alpha-particle immunotherapy by targeted α-emitters or α-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 ( 225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radio-nuclides. The daughters, especially bismuth-213 ( 213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195- 225 Ac generator. 223Ac, francium-221 ( 221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P <0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P <0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P <0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P <0.0001). Competitive antagonism by bismuth sub-nitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P <0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.

UR - http://www.scopus.com/inward/record.url?scp=19644399788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19644399788&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3096

DO - 10.1158/0008-5472.CAN-04-3096

M3 - Article

C2 - 15930310

AN - SCOPUS:19644399788

VL - 65

SP - 4888

EP - 4895

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -